Loading...
30 vitamin C COVID-19 controlled studies,
9 RCTs
https://c19vitaminc.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Thomas (RCT) -204%
3.04 [0.13-72.9]
death
1/48
0/50
Improvement, RR [CI] Treatment Control Thomas (RCT) 31%
0.69 [0.12-3.98]
hosp.
2/48
3/50
Thomas (RCT) 18%
0.82 [0.63-1.07]
recov. time
48 (n)
50 (n)
Zhao (PSM) 72%
0.28 [0.08-0.93]
progression
4/55
12/55
Zhao (PSM) -8%
1.08 [0.64-1.80]
viral time
55 (n)
55 (n)
Ried (RCT) 31%
0.69 [0.54-0.89]
no recov.
69/162
46/75
Krishnan 31%
0.69 [0.47-0.92]
death
40/79
52/73
Zhang (RCT) 50%
0.50 [0.20-1.50]
death
6/27
11/29
Zhang (RCT) 80%
0.20 [0.10-0.90]
death
5/27
11/29
Zhang (RCT) 50%
0.50 [0.20-1.80]
death
6/27
10/29
Zhang (RCT) 70%
0.30 [0.21-1.10]
death
5/27
10/29
Yüksel (PSM) 19%
0.81 [0.66-0.99]
death
31/42
40/44
Patel 29%
0.71 [0.43-1.14]
death
22/96
26/80
Patel 16%
0.84 [0.52-1.36]
death
15/30
16/27
Kumari (RCT) 36%
0.64 [0.26-1.55]
death
7/75
11/75
Kumari (RCT) 20%
0.80 [0.40-1.59]
ventilation
12/75
15/75
Kumari (RCT) 26%
0.74 [0.64-0.86]
recov. time
75 (n)
75 (n)
Kumari (RCT) 24%
0.76 [0.66-0.87]
hosp. time
75 (n)
75 (n)
Darban (RCT) 33%
0.67 [0.14-3.17]
progression
2/10
3/10
CT1
Darban (RCT) 6%
0.94 [0.84-1.06]
ICU
10 (n)
10 (n)
CT1
JamaliMog.. (RCT) 0%
1.00 [0.22-4.56]
death
3/30
3/30
JamaliMog.. (RCT) -25%
1.25 [0.37-4.21]
ventilation
5/30
4/30
JamaliMog.. (RCT) -31%
1.31 [1.03-1.66]
hosp. time
30 (n)
30 (n)
Gao 86%
0.14 [0.03-0.72]
death
1/46
5/30
Hamidi-Ala.. (RCT) 44%
0.56 [0.20-1.51]
death
5/40
9/40
CT1
Hamidi-Ala.. (RCT) 38%
0.62 [0.45-0.86]
hosp. time
40 (n)
40 (n)
CT1
Al Sulaiman (PSM) 15%
0.85 [0.61-1.12]
death
46/142
59/142
Mulhem -32%
1.32 [1.07-1.62]
death
157/794
359/2,425
Gadhiya -1%
1.01 [0.48-1.91]
death
19/55
36/226
Hakamifard (RCT) 46%
0.54 [0.14-2.08]
ICU
3/38
5/34
CT1
Hakamifard (RCT) 1%
0.99 [0.91-1.07]
hosp. time
38 (n)
34 (n)
CT1
Suna 21%
0.79 [0.44-1.41]
death
17/153
24/170
Suna -2%
1.02 [0.46-2.24]
ICU
11/153
12/170
Li (PSM) -11%
1.11 [0.79-1.54]
death
7/8
19/24
Vishnuram 54%
0.46 [0.24-0.86]
death
164/8,634
10/241
Özgünay 9%
0.91 [0.63-1.30]
death
17/32
75/128
Özgünay -1%
1.01 [0.79-1.29]
ventilation
23/32
91/128
Tan 25%
0.75 [0.10-2.98]
int./death
1/46
14/115
CT1
Tan 73%
0.27 [0.09-0.61]
ARDS
7/46
41/115
CT1
Zheng (PSM) -157%
2.57 [0.39-16.8]
death
12/70
7/327
Zheng -169%
2.69 [0.91-7.89]
death
12/70
7/327
Zheng (PSM) -35%
1.35 [0.88-2.08]
no improv.
18/70
16/327
Zheng -32%
1.32 [0.93-1.82]
no improv.
18/70
16/327
Simsek 44%
0.56 [0.23-1.35]
death
6/58
15/81
Simsek 10%
0.90 [0.55-1.46]
ICU
18/58
28/81
Tehrani (RCT) 87%
0.13 [0.01-2.25]
death
0/18
4/26
Tehrani (RCT) 18%
0.82 [0.60-1.13]
hosp. time
18 (n)
26 (n)
Baguma -48%
1.48 [0.41-4.70]
death
385 (n)
96 (n)
Behera 18%
0.82 [0.45-1.57]
cases
case control
Behera 29%
0.71 [0.40-1.26]
cases
case control
Louca 0%
1.00 [0.97-1.04]
cases
Holt -3%
1.03 [0.77-1.39]
cases
49/1,580
397/13,647
Abdulateef 19%
0.81 [0.37-1.78]
hosp.
8/132
22/295
Mohseni -44%
1.44 [1.22-1.71]
cases
34/43
307/560
vitamin C COVID-19 outcomes c19vitaminc.com Jan 18, 2022
1 CT: study uses combined treatment Favors vitamin C
Favors control
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
WCH
and
FLCCC provide
treatment protocols.
Submit
